Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claire M. Rice has a total of 411 co-authors. Here are the top co-authors by number of shared publications:

  • Neil Scolding

    Department of Internal Medicine, Gulu Medical School, Gulu University , Gulu , Uganda

    45 shared publications
  • Alastair Wilkins

    Department of Neurology, Southmead Hospital, and Clinical Neurosciences, University of Bristol, Bristol, United Kingdom

    18 shared publications
  • Kevin Kemp

    University of Bristol

    17 shared publications
  • Juliana Redondo

    Translational Health Sciences, Bristol Medical School, University of Bristol , Bristol , UK

    11 shared publications
  • Kelly Hares

    Clinical Neurosciences, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

    8 shared publications
  • Pamela Sarkar

    Clinical Neuroscience, Bristol Medical School, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Bristol, BS10 5NBww, UK; Department of Neurology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK

    8 shared publications

Latest Publications

  • Open Access

    Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model

    by Catalina Lopez Manzano, Ayman Sadek, Chris Cooper, Eve Tomlinson, Hanyu Wang, Claire Rice, Emma Tallantyre, Ananya Rao-Middleton, Penny Whiting, Howard Thom

    Background: Multiple sclerosis is an immune-mediated inflammatory disease, causing long-term disability in young adults. Most cases begin as relapsing–remitting multiple sclerosis. Some people have a form of relapsing–remitting multiple sclerosis known as highly active relapsing–remitting multiple sclerosis, defined as multiple sclerosis with unchanged or increased disease activity despite prior treatment with at least one disease-modifying therapy. Objectives: To appraise the clinical and cost-effectiveness of natalizumab [Tysabri ® (Biogen, Cambridge, MA, USA)] and natalizumab biosimilar [Tyruko ® (Sandoz)] for treating highly active relapsing–remitting multiple sclerosis compared to other disease-modifying therapy. Design: Systematic review with network meta-analysis and economic model. Searches last updated in April 2024. Results: We included 42 studies (22,409 participants): 40 in people with relapsing–remitting multiple sclerosis and 2 in highly active relapsing–remitting multiple sclerosis. Six studies also reported data separately for highly active relapsing–remitting multiple sclerosis. Only four studies evaluated natalizumab or natalizumab biosimilar; none provided data on those with highly active relapsing–remitting multiple sclerosis. Follow-up ranged from 4 to 36 (median 24) months. Most interventions reduced relapses (39 studies, 17 interventions) and magnetic resonance imaging lesions (19 studies, 11 interventions for gadolinium enhancing lesions and 17 studies, 12 interventions for T2-weighted lesions) compared to placebo. Alemtuzumab, ocrelizumab, cladribine, natalizumab, fingolimod and peginterferon beta-1a reduced disease progression compared to placebo (15 studies, 12 interventions). There were no differences in any adverse events (24 studies, 16 interventions), serious adverse events (31 studies, 15 interventions) or treatment-related adverse events (8 studies, no network meta-analysis) for any intervention compared to placebo. Fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b and peginterferon beta-1a were associated with an increased treatment discontinuation (29 studies, 13 interventions). There was little evidence for a difference in quality of life. There was no evidence of a difference between natalizumab and natalizumab biosimilar for relapse rates [rate ratio 0.65 (95% credible interval 0.33 to 1.23], gadolinium enhancing lesions [hazard ratio 1.29 (0.69 to 2.37)], T2-weighted lesions [hazard ratio 1.07 (0.73 to 1.57)], any adverse events [hazard ratio 1.06 (0.77 to 1.46)] or treatment discontinuation [hazard ratio 0.48 (0.13 to 1.76)]. Data in highly active relapsing–remitting multiple sclerosis were available for fingolimod, ocrelizumab, alemtuzumab, cladribine, interferon beta, autologous haematopoietic stem cell treatment and placebo. We also included one study on natalizumab conducted in a population that was close to our definition of highly active relapsing–remitting multiple sclerosis. All interventions except interferon beta-1a were associated with reduced relapse risk compared to placebo (six studies; seven interventions). Compared with natalizumab-intravenous, natalizumab biosimilar-intravenous and natalizumab subcutaneous, all treatments had greater net benefit at £20,000–30,000/quality-adjusted life-year, with the only exception being ocrelizumab, which had lower net benefits. Costs were generally higher on natalizumab than other treatments, though there was no difference in quality-adjusted life-years with 95% credible interval completely overlapping. The results and conclusions were unchanged under all sensitivities. VOI analysis found that the greatest contributor to decision uncertainty was the effectiveness of treatments. Conclusions: There is no direct evidence on the effectiveness of natalizumab or its biosimilar in patients with highly active relapsing–remitting multiple sclerosis. Limited data suggest similar effectiveness in patients with relapsing–remitting multiple sclerosis. The economic model found that natalizumab and natalizumab biosimilar were not cost-effective compared to any of the included comparators in highly active relapsing–remitting multiple sclerosis, with similar quality-adjusted life-years but higher costs, with the only exception being ocrelizumab. Future work: There is need for studies of natalizumab and natalizumab biosimilar in people with highly active relapsing–remitting multiple sclerosis. Study registration: The study is registered as PROSPERO CRD42024556838. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR165943) and is published in full in Health Technology Assessment ; Vol. 30, No. 60. See the NIHR Funding and Awards website for further award information.

  • Open Access

    Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): protocol for an international, multi-arm, multi-stage, platform, randomized controlled, double-blind, phase 3 clinical trial

    by Sean Apap Mangion, Charles Wade, Cheryl Pugh, Matthew Burnell, Rachel Burton, Mary Rauchenberger, Hannah Sweeney, Aoife Nolan, Monica Lewis, Elizabeth Brodnicki, et al.

    Introduction: Current treatments for multiple sclerosis (MS) do not address the pathological processes of neurodegeneration and chronic demyelination. This, coupled with the significant challenges of translating promising phase 2 results to phase 3 trial success, highlights the need for more efficient trial designs, such as platform multi-arm multi-stage (MAMS) trial approaches. MAMS trials have demonstrated success in areas such as oncology and infectious diseases. They are typified by a statistically robust core trial design that allows the addition of further treatment arms and utilisation of interim outcome analyses at pre-defined timepoints, to determine whether to terminate a treatment arm early or proceed to the final outcome analysis. To address the challenges in progressive multiple sclerosis (PMS) treatment discovery, the Optimal Clinical Trials Platform for PMS (OCTOPUS) trial was developed. It currently utilises MRI whole-brain atrophy as its interim outcome measure and the clinically relevant composite Expanded Disability Status Scale Plus (EDSS-Plus) as its final outcome measure. A rigorous and systematic drug selection process that assessed preclinical in vitro and animal model evidence, along with additional human data, led to the prioritisation of R/S-alpha lipoic acid (R/S-ALA) and metformin for testing against placebo, targeting pathobiological mechanisms relevant to PMS. All participants will be eligible to receive the current standard of care, including disease-modifying treatments (DMTs). Method and analysis: OCTOPUS will be a multi-centre, randomised, placebo-controlled, double-blind, phase 3, MAMS trial of participants aged 25 to 70 years (inclusive) with PMS and an EDSS score of 4.0 to 8.0 (inclusive). Steady progression must be the major cause of increasing disability rather than relapse in the preceding 2 years. In the trial’s first candidate drug cycle, participants will be allocated to R/S-ALA, metformin, or placebo in a 1:1:1 ratio. Cycle 1 active treatments will start as R/S-ALA 600 mg once daily, increased after 4 weeks to 600 mg twice daily, or metformin 1 g once daily, increased after 4 weeks to 1 g twice daily. The trial will be multinational, with participation from 28 hospitals across the UK and 10 hospitals in Australia. Clinician-reported measures will include: the EDSS-Plus and the individual components: EDSS, Timed 25 Foot Walk (T25FW); 9 Hole Peg Test (9HPT); Symbol Digit Modalities Test (SDMT); Sloan Low Contrast Visual Acuity (SLCVA); and Relapse assessment. Patient-reported outcomes include MS specific walking, fatigue, pain, and impact scales. We will include a health economic analysis. Analysis stage 1 will require randomisation of 125 participants per arm and utilise MRI percentage brain volume change (PBVC) with the Structural Image Evaluation using Normalisation of Atrophy (SIENA) technique from baseline to 78 weeks. A positive outcome in analysis stage 1 will detect a 0.15% per year whole brain atrophy difference with a one-sided alpha of 0.35 and power of 95%, ensuring a low probability of erroneously rejecting a treatment arm at this stage. Any arms that show a positive effect will proceed to final analysis stage 2. Analysis stage 2 will require 600 participants per arm. Participants included in stage 1 will also be included in the stage 2. Analysis stage 2 will evaluate time to 6-month confirmed disability progression in the EDSS-Plus, in order to detect a 25% hazard ratio reduction with 90% power and an alpha of 0.05. Assuming one treatment arm proceeds to analysis stage 2, the trial will recruit approximately 1,200 participants and last about 6 years. This is approximately two-thirds the size and half the duration of separately conducted two-arm phase 2 and 3 trials. Ethics and dissemination: The protocol was approved by the London Hampstead REC (22/LO/0622). This manuscript is based on protocol version 8.0 , 28 th August 2025. The findings of this trial will be disseminated through peer-reviewed publications and conference presentations. There will be a close communication strategy developed with the UK MS Society (MSS) and full patient and public involvement and engagement (PPIE). Trial registration: ISRCTN: 14048364 EudraCT number: 2021-003034-37 CTA 20363/0445 IRAS number: 1003943 Secondary identifying numbers: ND001, CPMS 54274 Strengths and limitations: The OCTOPUS trial will be the first platform multi-arm multi-stage phase 3 trial in PMS, offering the potential to significantly expedite clinical trial processes with advantages in cost- and time-efficiency, focusing specifically on the poorly treated pathobiological processes of chronic neurodegeneration and demyelination It will begin by assessing two promising drug candidates, immediate-release metformin and R/S-ALA, and will expand over the duration of the trial to include more drug arms under the same trial master protocol The flexible and statistically robust trial design means that several components of the design (such as the early analysis stage 1 interim outcome) can be updated in line with evolving scientific knowledge It will ultimately be the largest ever investigator-initiated phase 3 trial in PMS It will include a range of national and international trial sites, including neuroscience centres and district general hospitals It will have a high inclusion limit for age (up to 70 years) and disability (up to EDSS 8.0) Several components (the telephone EDSS and virtual patient-reported outcome measures) will be amenable to remote collection increasing inclusivity and thus addressing public and participant suggestions, while minimising the risk of missing data The main challenges in this trial design are the statistical and methodological complexity involved in design and implementation, and interpretation of interim trial results. Conclusion: The trial launched cycle 1 in January 2023. Analysis stage 1 recruitment of 375 participants was achieved in November 2024, enabling planned interim analysis stage 1 to be conducted by late 2026 ( Figure 1 ). On the 1 st of June 2026, in the UK, 24 sites are active with a further 4 in set-up as part of stage 2, and in the Australian extension, Platform Adaptive Trial for Remyelination and Neuroprotection in Multiple Sclerosis (PLATYPUS), 1 site is active, with 9 additional sites in set-up.


  • Open Access

    Defining Activity‐Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal

    by Catalina Lopez Manzano, Claire M. Rice, Emma Tallantyre, Chris Cooper, Hanyu Wang, Eve Tomlinson, Ayman Sadek, Ananya Rao‐Middleton, Howard Thom, Penny Whiting

    Background: Multiple sclerosis (MS) is commonly stratified into activity‐based subgroups to inform treatment decisions and health technology assessments (HTAs). However, the terminology and criteria used to define these subgroups, particularly ‘active’, ‘highly active’ and ‘rapidly evolving severe’ (RES) disease, are inconsistent across clinical trials and regulatory guidance, leading to ambiguity in practice and restricted treatment access. Our objectives were to review how activity‐based subgroups in MS are defined across NICE technology appraisals (TAs) and the randomised controlled trials (RCTs) that inform them, and to propose a preliminary framework for standardised terminology. Methods: We identified and reviewed NICE TAs of disease‐modifying therapies (DMTs) for MS and the RCTs included in those appraisals. We extracted and compared definitions used to characterise activity‐based MS subgroups, and classified them by key components such as relapse history, MRI findings and treatment status. We summarised our findings and highlighted points of consensus and controversy. Results: Definitions varied widely, especially for ‘highly active’ RRMS and active SPMS. While most TAs used consistent criteria for ‘active’ and ‘RES’ RRMS disease, definitions in RCTs were heterogeneous. We identified frequent overlaps in terminology and proposed a simplified framework comprising three distinct but overlapping subgroups for RMS: active RRMS/RRMS, highly active RRMS (HARRMS) and rapidly evolving severe RRMS (RES‐RRMS). Conclusions: Standardised definitions are urgently needed to improve evidence synthesis, inform regulatory guidance and ensure equitable treatment access. We propose a formal consensus process to consolidate this framework for use in future research, HTAs and treatment pathways.

  • Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)

    by Emma C Tallantyre, Sarah M Planchon, Harriet Howard, John Mays, Nadia Frowd, Jeffrey A Cohen, Alasdair Coles, Carrie M Hersh, Deborah M Miller, Meredith Dever, et al.

    Background: There is growing support for high-efficacy disease-modifying therapy (DMT) in multiple sclerosis (MS), but escalation (ESC) approaches remain common. Objective: To describe decision-making in a pragmatic trial of early high-efficacy treatment (EHT) versus ESC. Methods: DELIVER-MS is a multi-center, pragmatic, randomized controlled trial (RCT) with a parallel observational study (OBS), which enrolled treatment-naïve people with RRMS in 31 UK/US sites. Primary outcome was as follows: 36-month brain volume loss according to initial treatment approach (EHT vs. ESC). Stepwise multivariable logistic regression was used to predict participation in RCT versus OBS and choice of EHT versus ESC within the OBS cohort. Results: In total, 816 people with MS were enrolled. Participants declined randomization due to preference for a particular DMT (85%), efficacy concerns (20%), and safety concerns (9%). RCT versus OBS participation was associated with lower relapse rate ( p = 0.043) and greater brain parenchymal fraction ( p = 0.002). Among 374 in the OBS cohort, 125 (33%) chose ESC and 249 (67%) chose EHT. People commencing EHT had higher education attainment ( p < 0.001) and relapse rate ( p = 0.025). Conclusion: Baseline DELIVER-MS data demonstrate that participants with milder disease are more likely to participate in RCT. The choice of EHT versus ESC was associated with demographic factors and disease activity. Clinical trial registration: NCT03535298

  • The 2024 McDonald criteria for the diagnosis of multiple sclerosis: implications for clinical practice

    by Tarunya Arun, Kate Petheram, Tasanee Braithwaite, Wallace J Brownlee, Helen L Ford, Paul Gallagher, Stella Hughes, Jacqueline Palace, Claire M Rice, S Anand Trip, et al.

    The 2024 revisions to the McDonald criteria mark a major shift in the diagnosis of multiple sclerosis (MS), reflecting advances in imaging and biomarker science. The updated framework adopts a more biologically anchored approach, integrating radiological and cerebrospinal fluid evidence to enable earlier and more accurate diagnosis. Key changes include recognition of the optic nerve as a fifth anatomical site for dissemination in space, incorporation of advanced MR imaging markers such as the central vein sign and paramagnetic rim lesions to improve specificity, and acceptance of the kappa free light chain index as a quantitative alternative to oligoclonal bands. In selected patients with highly characteristic clinical and imaging features, MS may now be diagnosed without demonstration of dissemination in time, reducing diagnostic delay. A unified pathway across relapsing and progressive phenotypes, including children, promotes consistency, while defined pathways also allow diagnosis in certain asymptomatic individuals, including those with radiologically isolated syndrome, when supported by biomarkers. Implementation will require access to advanced imaging, standardised laboratory testing, multidisciplinary expertise and careful clinical judgement to minimise misdiagnosis and ensure equitable access.


  • Open Access

    Processes of Sharing and Relating of Women With Multiple Sclerosis Through a Group Psychological Intervention: A Longitudinal Qualitative Study

    by Evangelia Fragkiadaki, Isabella E. Nizza, Rachel A. Starr, Jonathan A. Smith, Claire Rice, Nikki Cotterill

    Purpose: Relationships are important for people with Multiple Sclerosis (MS). Social support contributes to well‐being, and psychological group interventions show positive findings on quality of life, coping, and self‐efficacy. The current article aims to report sharing and relating processes in an online group integrative psychological intervention named MyMS‐Ally that contributed to positive change in five women with MS who participated in the study. Methods: This study followed the principles of Longitudinal Interpretative Phenomenological Analysis (LIPA). Five women living with MS participated in an 8‐week online integrative psychological intervention group. Qualitative data were collected at three different time points: before the start of the intervention, post‐intervention, and at the 3‐month follow‐up. The findings presented here are part of a mixed‐method feasibility and acceptability study for the MyMS‐Ally intervention. Results: The longitudinal group experiential theme ‘transitioning from concealing MS to embracing its relational effect’ was developed to capture the changes participants experienced in their relationships with people with and without MS following their engagement with the MyMS‐Ally intervention. From the point of hiding their symptoms and needs, they became more open to communication in their relationships. The temporal changes of the five participants were grouped under the three time points. Discussion: The findings demonstrate the pathways participants went through towards sharing and relating with their MS and the group processes they found most impactful. Processes were deemed more important than the psychological techniques employed during the intervention. Implications for the development of group psychological interventions for people living with MS and their evaluations are also discussed.

  • Cerebral venous sinus thrombosis complicating IgG4-related hypertrophic pachymeningitis

    by Lu Yang, Stefania Kaninia, Kathryn Urankar, William Brown, Konrad Szewczyk-Krolikowski, Claire M Rice


  • Open Access

    Trajectories of change in experiences of multiple sclerosis: insights from an online group psychological intervention

    by Evangelia Fragkiadaki, Isabella E. Nizza, Rachel Starr, Jonathan A. Smith, Claire Rice, Nikki Cotterill

    Literature on psychological interventions for people affected by MS highlights the necessity for integrative and flexible approaches. Here, we present a subset of the qualitative findings of a feasibility and acceptability study of an eight-week online group psychological intervention, MyMS-Ally. The study followed Longitudinal Interpretative Phenome-nological Analysis for data collection and analysis. Five participants who took part in one group were interviewed three times; before the intervention, post-intervention and at follow-up (three months). Data were analysed on a case-by-case basis. Findings revealed idiosyncratic trajectories of change. Participants with invisible disability initially avoided and fought their MS. Post-intervention, they acknowledged their condition as part of themselves and their lives, developing compassion towards their limitations and needs. Participants with visible disability initially adopted a judgemental attitude towards their growing needs and loss of independence, moving to more empowered and accepting positions following the group intervention. Despite the limitations due to the small sample and lack of diversity in our sample, the qualitative findings presented provide significant insights into change participants experienced. The results highlight the need to consider self-concept and construction of identity when developing and evaluating individualised psychological interventions for people with MS.


  • Open Access

    Acute retinal necrosis associated with dimethyl fumarate

    by Christopher Paisey, Karen Curtin, Simon J Epps, Claire M Rice

    Background: The full range of side effects of disease-modifying treatment for multiple sclerosis (MS) remains to be determined. To date, four serious varicella zoster virus (VZV) infections have been reported in association with dimethyl fumarate (DMF). Report: A 44-year-old man on DMF for relapsing remitting MS presented with monocular pain and visual impairment. Ophthalmological examination revealed panuveitis with arteritis, retinitis and vitritis. Vitreous PCR was positive for VZV confirming the clinical impression of acute retinal necrosis (ARN). Discussion: ARN due to VZV may mimic optic neuritis in people on disease-modifying therapy for MS.


  • IgG4-related disease in the nervous system

    by Lu Yang, R J Paul Smith, Neil J Scolding, Claire M Rice

    IgG4-related disease (IgG4-RD) is a recently described multisystemic disorder with a spectrum of manifestations that continue to be described. Nonetheless, there are recognised distinct patterns of disease. Neurological involvement is rare, particularly in isolation, but IgG4-RD may present with orbital disease, hypophysitis or pachymeningitis. Typically, it is highly responsive to treatment. This review highlights neurological manifestations of IgG4-RD and emphasises the importance of a high index of clinical suspicion to facilitate investigation and appropriate management, avoiding irreversible tissue damage and neurological dysfunction. We present a treatment algorithm for suggested management of IgG4-RD affecting the nervous system.